SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
HENDERSON, Nev., May 01, 2018 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion. Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.
“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP. “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”
About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/
About United Health Products, Inc.
United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464
